Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Posts Draft Guidance On Biosimilars; Seeks Public Comment

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan's Ministry of Health, Labor and Welfare Sept. 17 posted draft guidance on follow-on biologics, or biosimilars, a move that could make Japan among the first group of large economies to set a safety and regulatory framework for the new copycat breed of biologic therapies

You may also be interested in...



Merck Eyes Emerging Biosimilars Market In Japan

Merck is the latest major drug maker to leap into the Japanese generics foray, as the Whitehouse Station, NJ-based company announced plans to launch its first biosimilar drug for anemia in Japan as early as 2012

Merck Eyes Emerging Biosimilars Market In Japan

Merck is the latest major drug maker to leap into the Japanese generics foray, as the Whitehouse Station, NJ-based company announced plans to launch its first biosimilar drug for anemia in Japan as early as 2012

Merck Eyes Emerging Biosimilars Market In Japan

The company's Japanese subsidiary Banyu Pharmaceutical has started domestic trials for its generic erythropoietin, poised to be Merck's first biosimilar launch.

Related Content

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel